Alejandro Gil Escolano, the Head of Regulatory Affairs for Curaleaf International, represented Curaleaf at the Farmaforum 2025 in Madrid.
Notably, he shared insights into the evolving medical cannabis landscape, highlighting the industry’s shift toward greater normalisation.
While international regulations remain fragmented, we’re seeing more countries like Spain, France and Ukraine start to develop their own frameworks. This trend underscores a move towards wider acceptance alongside more established markets, like Germany, the UK, and Australia.
The panel emphasised that to unlock the sector’s full potential, we need a clear, aligned regulatory approach.
Crucially, the conversation reaffirmed our core belief – patient needs should always lead. To address this our team works tirelessly to widen product formats and develop real-world evidence using the UK Medical Cannabis Registry Curaleaf Clinic to help drive progress and inform future practices.
We’re proud to be contributing to an evidence-based future for medical cannabis.
